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Abstract
Seroepidemiological surveys show that the prevalence of human herpesvirus 8 (HHV-8) infection mostly varies in
various geographical areas and reflects the local incidence of classic and endemic KS, being widespread in sub-
Saharan Africa and Mediterranean countries and uncommon in the USA and Northern Europe. In the Middle East
only few populations, such as Ashkenazi and Sephardic groups in Israel, have been adequately evaluated for HHV-8
seroprevalence. Among Iranian population a striking higher seroprevalence of HHV8 has been reported among
haemodialysis (16.9%), renal transplant recipients (25%) and HIV (45.7%) patients compared to blood donors (2%).
Kaposi’s sarcoma (KS) is the rarest cancer in Iran, with an annual age-standardized incidence varying from 0.10 to
0.17 per 100,000 in males and from 0.06 to 0.08 per 100,000 in females. KS, however, is one of the most important
malignancies in Iranian renal transplanted patients affecting up to 2.4% of organ recipients. The epidemiology of
HHV8 and KS in Iran needs further evaluation. While the high prevalence of HHV-8 antibodies in HIV positive and
haemodialysis individuals may be attributed to high-risk sexual behavior and polytransfusions, respectively,
unknown determinants may be responsible for high seroprevalence of HHV8 and high incidence of KS in solid
organ recipients. A global survey on HHV8 seroprevalence in Iran is mandatory to define co-factors associated with
HHV8 infection and KS risk in the general Iranian population and in specific patient groups.
Introduction
Kaposi’s sarcoma (KS) is a mesenchymal tumor invol-
ving blood and lymphatic vessels that was first described
in Eastern Europe in the late 19th century [1] and classi-
cally considered an indolent disease of elderly men. Now
days, Kaposi’s sarcoma has been classified in four differ-
ent clinical and epidemiological forms [2]: 1) Classic KS,
mainly occurring in elderly men of Mediterranean or
Eastern European origin [3-6]; 2) African-endemic KS
[6-9]; 3) Iatrogenic KS, developing in solid organ trans-
plantation recipients [6,10-12] and 4) Epidemic or
AIDS-associated KS [6,13-15]
In 1994 Chang et al. identified fragments of the Kapo-
si’s sarcoma-associated herpesvirus (KSHV) genome in
epidemic KS tissues, subsequently called human herpes-
virus type 8 (HHV-8) [16]. HHV-8 is considered to be
the etiological agent of all forms of Kaposi’ss a r c o m a
[2], and has been consistently associated with two types
of lymphoproliferative disease, namely body cavity-based
lymphoma [17] as well as multicentric Castelman’sd i s -
ease [16,18].
Seroepidemiological surveys have shown that HHV-8
infection is not ubiquitous [19]. The virus is less preva-
lent in northern Europe, North America, and most of
Asia, and is more frequent in the Mediterranean area
and parts of South America, and highly prevalent in
sub-Saharan Africa [20-23]. Several studies have been
performed in some Middle Eastern countries. In Israel
seropositivity of HHV-8 has been ranging from 8.4% to
22% in healthy individuals [24,25]. In Saudi Arabia sero-
prevalence of HHV-8 was reported at 1.7% and 18% in
healthy subjects and renal transplant recipients, respec-
tively [26].
Few studies have been performed on the HHV-8 dis-
tribution and incidence of Kaposi’s sarcoma in Iran.
This study aimed to recapitulate available data on the
seroepidemiology of HHV-8 and incidence of KS in the
Iranian population. A systematic review of the published
articles from January 1980 to December 2010 was con-
ducted to assess the seroprevalence of HHV-8 and the
incidence of KS in Iran. Data were identified by searches
of Medline, Current Contents, PubMed, and references
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sarcoma” or “HHV-8”, and “Iran”.
Epidemiology of classic Kaposi’s sarcoma in Iran
Data from the National Cancer Registry of Iran have
reported that KS is the rarest cancer among Iranians
[27]. Only 50, 44, and 61 KS cases were reported in the
National Cancer Registry in 2004 [27,28], 2005 [27] and
2006 [27,28] respectively, and 101 new cases have been
registered in Tehran Population Based Cancer Registry
from 1998-2002 [27,29]. The annual age-standardized
incidence rate was reported to be from 0.10 to 0.17 per
100,000 in males and from 0.06 to 0.08 per 100,000 in
females [27]. Peak incidence has been reported at ages
of 50-79 years. The male/female ratio in different
reports varies from 3.2:1 to 1.8:1 and the elderly might
be a common associated factor for KS [27]. There were
no published reports about AIDS-KS in Iran.
Worldwide KS accounts for only 0.02% to 0.07% of all
malignancies in the general population [30]. The regions
with the highest incidence are Africa, where KS repre-
sents 3% to 9% of all cancer cases [31], Mediterranean
and Eastern European areas, with specific geographic
foci in Italy, Greece, and Israel [4,5].
Epidemiology of post-transplant Kaposi’s sarcoma in Iran
The incidence of KS in kidney recipients has increased
following an enormous increase in the number of kidney
transplantations during the recent decades, particularly
of those of Mediterranean descent [32]. Post-transplan-
tation KS develops in 23% to 28% of HHV8 seropositive
patients and in only 0.7% of seronegative patients
[32-34].
The rate of chronic kidney disease and renal trans-
plantations has increased during the last two decades in
Iran [34-36]. About 1.14-6% (mean = 2.8%) of Iranian
renal transplant recipients develop cancer lesions,
mostly skin cancers (Table 1) [37-43]. These findings
are consistent with other report in Middle Eastern coun-
tries. The prevalence of all malignancies in renal trans-
plant recipients was 1.9% in Pakistan [44], 4% in Turkey
[45], 6.8% in Saudi Arabia [46], 4.8% in Kuwait [47],
5.9% in Iraq [48], and 1.7% in Jordan [49].
KS is one of the most common cancers after renal
transplantation in Iran [36] representing 28.5-70%
(mean = 42.2%) of all post-transplant malignancies
(Table 1) [37-43]. Other reports from the Middle East-
ern region showed that KS was the most common post-
transplantation malignancy with frequencies of 25% [45]
and 68% in Turkey [50], 44% in Pakistan [51], and 50%
in Iraq [48].
In Iran, incidence of KS among renal transplants var-
ied from 0.45% to 2.4% in different studies (Table 1)
[37,38,40-43,52-55]. In other countries of this region,
the figures were 0.55% in Jordan [49], 3.2% in Turkey
[56] and 4.9% in Saudi Arabia [46]. The incidence of KS
was 0.7% [56], 1.7% [57] and 3.9% [58] among renal
transplant recipients in Taiwan, Greece and South
Africa, respectively. Therefore, the incidence of KS fol-
lowing kidney transplantation varies significantly in dif-
ferent geographic areas [59], and this is supporting the
theory of ethnic or environmental factors in its patho-
genesis. Globally, KS is most often seen in transplant
recipients of Mediterranean, Jewish, Arabic, Caribbean,
or African descent and the reported incidence ranges
from 0.5% in most Western countries (including the
United States) up to 5.3% in Saudi Arabia [32].
The KS incidence among Iranian transplants recipients
had a peak during the first 2 years post transplantation.
The time interval between transplantation and onset of
Table 1 List of published data on the incidence of Kaposi’s sarcoma in renal transplanted patients in Iran
City Renal
Transplants
Male/
Female (N)
Post-transplant
Malignancies (%)
KS
cases
(%)
Male/
Female
(N)
Cutaneous/
visceral (N)
Study period References
Tehran 681 438/243 - 5 (0.73) 3/2 - 2000-2002 [52]
Tehran 100 53/47 6 (6) 2 (2.0) 2/0 - 2000-2002 [39]
Tehran 2211 - - 10 (0.45) 8/2 8/2 1984-2007 [53]
Tehran 1750 - 28 (1.6) 13 (0.74) - - 1984-1999 [42]
Tehran 2050 - - 18 (0.87) 13/5 18/1 1984-1999 [54]
Ahwaz 580 330/250 20 (3.4) 14 (2.4) 11/3 11/3 - [40]
Babol 380 - 12 (3.15) 5 (1.3) - - 1999-2005 [41]
Shiraz 892 537/355 21 (2.3) 6 (0.68) 5/1 4/2 1988-2001 [38]
Tehran, Urmia, Babol, Sari,
Tabriz, Hormozgan,
Kerman
7,939 5018/2921 162 (2.04) 55 (0.69) 33/22 48/7 1984-2007 [37]
Tehran, Urmia, Babol, Sari,
Tabriz, Hormozgan,
Kerman, Isfahan, Ahwaz
11,255 7109/4146 128 (1.14) 77 (0.68) 48/29 - 1984-2008 [43]
Jalilvand et al. Infectious Agents and Cancer 2011, 6:5
http://www.infectagentscancer.com/content/6/1/5
Page 2 of 6KS was relatively early compared to other skin tumors.
This observation is in agreement with other studies
from the Middle East region reporting appearance of KS
lesions in 6.5 to 27 months following kidney transplan-
tation [26].
The mean-age of Iranian renal transplants developing
KS is below 50 years, which is lower than that of
patients with classic Kaposi’s sarcoma (50-79 years).
This finding is consistent with data reported by other
studies on renal transplant patients from different
regions of the world [30,32,45,60,61].
About 90% percent of transplant recipients affected by
KS present cutaneous or mucosal lesions or both types.
Visceral involvement occurred in 25% to 30% of kidney
transplant patients [62]. Visceral lesions affected 10% of
patients and predominantly involved the lymph nodes,
gastrointestinal tract, and lungs [63]. In agreement with
these worldwide studies, 80% of Iranian transplant reci-
pients with KS developed cutaneous lesions. Visceral
involvement was observed in 20% of patients (Table 1)
[37,38,40,53,54].
Most cases of post-transplantation KS develop as a
result of viral reactivation, since more than 80 percent
of transplant recipients with KS are seropositive for
HHV-8 before transplantation [34,64]. Renal recipient
patients who were seropositive for HHV-8 before trans-
plantation, have a risk to develop KS of 23% to 28% that
is significantly higher compared to risk of 0.7% in
patients who are seronegative before receiving a kidney
transplant [32-34,65].
Seroepidemiology of HHV-8 in Iran
Few serological survey on HHV-8 infection have been
performed in Iran [55,66]. One study by Gharehbaghian
et al. analyzed three groups of patients including haemo-
dialysis patients, recruited in 2004 at the Immam-Kho-
meini hospital; HIV positive subjects, enrolled at the
Immam-Khomeini hospital from July 2003 to June 2004;
and blood donors, enrolled consecutively in a single day
(June 28
th, 2004) at the Research Center of Iranian
Blood Transfusion Organization. The 256 blood donors,
enrolled without any obligations, represented the 25.6%
of blood samples screened on that day. All sera were
tested for the presence of antibodies against HHV-8
lytic antigens by HHV-8 IgG EIA and by HHV-8 IgG
IFA commercial kits (Biotrin, Ireland) as for manufac-
turer’s instructions and each sample defined as “posi-
tive” if tested positive to both assays. The sensitivity of
EIA and IFA tests was 90.4% and 100%, respectively, as
reported in the manufacturer’s catalogue. The specificity
of EIA and IFA was 93% and 94%, respectively.
Among the 256 healthy Iranian blood donors (242
males and 14 females with mean age of 38 years, range
18-60 years) only 5 (2%, CI 95% = 0.003-0.03), including
4 males and one female, were positive for HHV-8 anti-
bodies. Conversely, among the 118 haemodialysis
patients (63 males and 53 females with mean age of 50
years), 20 (16.9%, CI 95% = 0.1-0.23) tested positive,
including 8 males and 12 females. In the HIV positive
group (33 males and 2 females, the range of age 20-40
years) 16 out of the 35 patients (45.7%, CI 95% = 0.29-
0.62), all males, were positive for HHV-8 [55]. Also, fre-
quency of HHV-8 positivity was not statistically signifi-
cant different among haemodialysis patients stratified by
number of transfusions (P = 0.36) [55]. Crude odds
ratios and 95% confidence intervals were used to com-
pare HHV-8 seroprevalence in different groups (Table
2). Overall, there was a statistically significant higher
risk of HHV-8 seropositivity in haemodialysis (OR =
10.24, 95% CI: 3.5 - 32.1) and HIV (OR = 42.27, 95%CI:
12.7 - 150) patients compared to blood donors, although
several variables between the three enrolled groups can-
not be excluded.
Low prevalence of HHV-8 in blood donors may indi-
cate that virus is not widespread in this population;
however, this study is not sufficient to determine the
extrapolation of the true prevalence of HHV-8 in Ira-
nian healthy population. Blood donors in above men-
t i o n e ds t u d yw e r eo n l yf r o mT e h r a na n di tm a yb e
representative of the prevalence of HHV-8 in Tehran
rather than Iran. The distribution of this virus probably
is not ubiquitous in all over the Iran, so it is recom-
mended to perform surveillance studies on different
populations living in different areas of Iran in order to
determine the global seroprevalence of HHV-8. Also
blood donors commonly have not considered as persons
Table 2 Seroprevalence of HHV-8 among blood donors, haemodialysis, HIV-positive and renal transplants Iranian
patients
Study Population (N) Male/Female (N) HHV-8 positive cases (%) HHV8 detection Methods References
Blood donors (256) 242/14 5/256 (2%) Lytic [IFA-EIA]* [55]
Haemodialysis patients (118) 63/55 20/118 (16.9%) Lytic [IFA-EIA]* [55]
Renal transplants (100) 60/40 25/100 (25.0%) LANA [IFA]** [66]
HIV positive patients (35) 33/2 16/35 (45.7%) Lytic [IFA-EIA]* [55]
* Positivity was based on positive test of both EIA and IFA assays;
** Positivity was based on positivity to a single LANA IFA assay;
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populations be general population rather than blood
donors to estimate more relevant prevalence of HHV-8
infection.
In another study by Ahmadpoor et al., 100 serum
from Iranian renal transplant recipients (60 male, 40
female) were analyzed for antibodies against the latent
nuclear antigen of HHV-8 [66] and 25% tested seroposi-
tive for HHV-8 (Table 2). The mean age was 41.1 years
(range, 17-74 years) and there was a statistically signifi-
cant difference in HHV-8 seropositivity among recipi-
ents older than 55 years (P = 0.02). In particular, 8 out
of 17 (47%) patients were seropositive in the group
older than 55 years, versus 17 out of 83 (20%) patients
in the group younger than 55 years. There were no sig-
nificant differences in HHV-8 seropositivity regarding
sex. Seropositive and seronegative patients were fol-
lowed for 16 months and only one HHV-8 seropositive
patient (1/25) developed Kaposi’s sarcoma [66]. The risk
of HHV8 infection in transplanted patients is signifi-
cantly higher (OR = 16.73, 95% CI: 5.8 - 51.8) compared
to blood donors, although different HHV8 detection
methods were used (Table 2). These findings are consis-
tent with other studies in our region reporting 18% and
28% HHV8 seroprevalence among renal transplant reci-
pients in Saudi Arabia [26,67].
Different rates of HHV-8 infection have been reported
in various populations in the world. The prevalence of
HHV8 in healthy individuals was found to be 1.3%-4.4%
in Southeast Asia and the Caribbean regions and > 40%
i nA f r i c a[ 6 8 - 7 0 ] .I nI n d i aap r e v a l e n c eo f3 . 7 %a n d
2.3% has been reported in healthy individuals and HIV
positive patients, respectively [68]. In one study from
Saudi Arabia the seroprevalence of HHV-8 in healthy
Saudi national’s people was reported to be 1.7% [26]. In
Europe, the prevalence of HHV-8 was found to be low-
est in Spain or Greece (6%-8%) and highest in Italy
(20.4%) [71-75]. Approximately 50% of the adult popula-
tion of Brazilian Amerindians was reported to have anti-
bodies to HHV-8 [76], compared with only 11% of HIV-
negative injection drug users in Argentina [77].
Conclusions
In conclusion, in Iran a high prevalence of HHV8
infection has been observed in several risk groups such
as haemodialysis, renal transplant and HIV-positive
patients. KS incidence among renal transplant patients
is as high as that observed in transplanted patients
from endemic regions for KS. A future study including
a large population from different regions of Iran is
needed in order to define co-factors associated with
HHV8 infection and KS risk specific patient groups in
Iran.
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